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Abstract 1 
 2 
Objective To investigate changes in serum cardiac troponin I (cTnI) concentrations in 3 
dogs in which medetomidine was used for sedation or for premedication prior to 4 
anaesthesia with propofol and sevoflurane. 5 
Study design Prospective clinical study. 6 
Animals A total of 66 client-owned dogs. 7 
Methods The dogs were sedated with medetomidine (0.04 mg kg-1) intravenously (IV) 8 
(group M; n = 20) and left to breath room air or anaesthetized with propofol (6.5 ± 0.76 9 
mg kg-1 IV) and sevoflurane (4.5% vaporizer setting) in oxygen (group P+S; n = 20) or 10 
with medetomidine (0.04 mg kg-1 IV), propofol (1.92 ± 0.63 mg kg-1) and sevoflurane 11 
(3% vaporizer setting) in oxygen (group M+P+S; n = 26), respectively. After 35 12 
minutes, medetomidine was antagonized with atipamezole (0.1 mg kg-1 13 
intramuscularly). Blood samples for serum cTnI determination were taken before 14 
sedation or anaesthesia, 6 and 12 hours and 4 days thereafter. Serum cTnI 15 
concentrations were measured with the Architect STAT Troponin-I assay.  16 
Results Before sedation or anaesthesia, cTnI concentrations were above the detection 17 
limit in 22 out of 66 (33%) of dogs. Compared to basal values, cTnI concentrations 18 
significantly increased at 6 and 12 hours in all groups and at day 4 in group M. There 19 
were no differences in cTnI concentration between groups at baseline, at 6 hours and at 20 
4 days. At 12 hours, cTnI concentrations were significantly higher in groups M and 21 
P+S, respectively, compared to group M+P+S. 22 
Conclusions and clinical relevance Oxygenation during anaesthesia and reduction of 23 
propofol and sevoflurane dose due to the sparing effects of medetomidine might have 24 
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played a role in alleviation of myocardial hypoxic injury as indicated by the less severe 25 
and short-lived increase of cTnI in the M+P+S group. 26 
 27 
Keywords cardiac troponin I, dogs, medetomidine, propofol, sevoflurane 28 
 29 
Introduction 30 
 31 
Cardiac troponin I (cTnI), an inhibitory subunit of troponin, is a highly sensitive and 32 
specific marker of myocardial cell injury in dogs (Burgener et al. 2006). In healthy dogs 33 
cTnI is present at low concentrations in the blood and provides information about 34 
cardiac-specific injury (Sleeper et al. 2001; Winter et al. 2014; Winter et al. 2017). 35 
During surgery under general anaesthesia, subclinical myocardial damage and leakage 36 
of cTnI from myocytes may occur in dogs (Pelander et al. 2008; Cilli et al. 2010; 37 
Verbiest et al. 2013). The relative effect of surgery and general anaesthesia on cTnI 38 
leakage from myocytes is still not known. To exclude the possible influence of surgical 39 
trauma, we investigated the effect of anaesthetic drugs on serum TnI concentration in 40 
dogs sedated for radiographic examination or anaesthetized for gastroscopy.  41 
The effect of anaesthesia with propofol and sevoflurane with or without premedication 42 
with medetomidine on serum cTnI concentration in dogs has not yet been reported. 43 
Premedication with medetomidine decreases the anaesthetic requirements of propofol 44 
(Vainio 1991; Cullen & Reynoldson  1993; Lagerweij et al. 1993; Sap & Hellebrekers 45 
1993; Hammond & England  1994; Thurmon et al. 1994). Dexmedetomidine, the active 46 
enantiomer of the racemate medetomidine, causes a dose-dependent decrease in 47 
sevoflurane minimum alveolar concentration in dogs (Moran-Muñoz et al. 2014; Hector 48 
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et al. 2017). We hypothesized that in dogs premedicated with medetomidine 49 
[administered intravenously (IV) at 0.04 mg kg-1] and anaesthetized with propofol and 50 
sevoflurane, the increase in serum cTnI concentration would be less pronounced 51 
because of anaesthetic sparing effects in comparison to dogs anaesthetized with 52 
propofol and sevoflurane only. 53 
However, it is not known whether medetomidine alone causes subclinical myocardial 54 
damage and resultant cTnI release into the bloodstream. Singletary et al. (2010) 55 
demonstrated that sedation with medetomidine and butorphanol does not cause a 56 
significant rise in serum cTnI concentration in dogs. They used medetomidine at a 57 
relatively low intravenous dose of 0.01 mg kg-1 and monitored cTnI concentration up to 58 
24 hours after administration. The cardiovascular effects of medetomidine, bradycardia 59 
in particular, are dose related (Vainio & Palmu 1989; Cullen & Reynoldson 1993). We 60 
therefore investigated changes of serum cTnI concentrations in dogs in which 61 
medetomidine (0.04 mg kg-1 IV) was used for sedation or for premedication prior to 62 
anaesthesia with propofol and sevoflurane. None of the studies that investigated cTnI in 63 
dogs sedated with medetomidine (Singletary et al. 2010) or anaesthetized with various 64 
anaesthetic protocols (Saunders et al. 2009; Cilli et al. 2010; Verbiest et al. 2013) 65 
monitored serum cTnI concentration more than 24 hours after sedation or anaesthesia. 66 
Hence, in our study, serum concentration of cTnI was monitored at 6 hours, 12 hours 67 
and 4 days after basal measurements. 68 
 69 
Materials and methods 70 
 71 
Animals 72 
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Client-owned dogs of various breeds with no cardiac disease, as confirmed by 73 
echocardiography and electrocardiography examination, presenting for radiography as 74 
part of orthopaedic examination under sedation or general anaesthesia for gastroscopy 75 
were recruited for this study. All eligible dogs with informed owner consent that were 76 
presented between January and June 2015 were included. An a priori sample size 77 
calculation was not performed.   78 
The study was approved by the Local Ethical Committee at University of Belgrade 79 
(Licence No. 01-19/11). Dogs were classified as 1 or 2 according to the American 80 
Society of Anesthesiologists’ classification system. A pre-sedation complete blood 81 
count, white cell differential count and serum biochemistry profile including urea, 82 
creatinine, total protein, albumin, glucose, creatin kinase, alkaline phosphatase, 83 
aspartate aminotransferase and alanine aminotransferase (data not shown) were 84 
determined to exclude underlying diseases that might affect cTnI concentration. 85 
 86 
Study protocol 87 
A 22- or 20-gauge catheter was placed in the left or right cephalic vein. Dogs presenting 88 
for radiography (group M) were sedated with 0.04 mg kg-1 IV medetomidine (Domitor; 89 
Orion Pharma, Finland) and breathed room air during sedation. After 35 minutes, 90 
medetomidine was antagonized with 0.1 mg kg-1 atipamezol (Antisedan; Orion, 91 
Finland) administered intramuscularly (IM).  92 
Dogs that presented for gastroscopy were randomly allocated (manual randomization 93 
with a toin coss) to either group P+S or group M+P+S. Dogs in group P+S were 94 
administered IV propofol (Diprivan; Astra Zeneca Ltd, UK) at  6 to 8 mg kg-1 to allow 95 
placement of an endotracheal tube. Anaesthesia was maintained with 4.5% sevoflurane 96 
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in oxygen (vaporizer setting, Sevorane; Abbott, Canada). Dogs in group M+P+S were 97 
premedicated with medetomidine (0.04 mg kg-1 IV), 2 minutes later 1 to 3 mg kg-1 IV 98 
propofol was administered to allow placement of an endotracheal tube. Anaesthesia was 99 
maintained with sevoflurane at 3% (vaporizer setting) in oxygen. A non-rebreathing  100 
(Mapleson F, body weight below 3 kg) or circle breathing system (body weight above 3 101 
kg) were used as appropriate. All dogs were allowed to breathe spontaneously during 102 
anaesthesia. Duration of anaesthesia for gastroscopy was standardized to 35 minutes in 103 
both groups of dogs, and afterwards 0.1 mg kg-1 IM atipamezol was administered to 104 
group M+P+S.  105 
The electrocardiogram, heart rate (HR), haemoglobin oxygen saturation (SpO2) and 106 
non-invasive blood pressure were monitored with a monitor (Mindray PM-9000 Vet; 107 
Shanghai International Holding Corp. GmbH, Germany). Respiratory rate (fR) was 108 
monitored by observation of chest movements in group M. Dogs undergoing general 109 
anaesthesia were additionally monitored with a capnograph and thermometer. 110 
Measurements of HR and mean arterial blood pressure (MAP) were recorded every five 111 
minutes during sedation or anaesthesia. For the purpose of statistical analysis 112 
measurements of both variables at 5, 15, 25 and 35 minutes were used. Hartmann’s 113 
solution (Hemofarm AD, Serbia) was administered during sedation or anaesthesia at 5 114 
mL kg-1 hour-1. 115 
Blood samples for determination of serum cTnI (basal values) were taken from the 116 
cephalic vein and collected into serum separator tubes (Vacuette; Greiner Bio-One, 117 
Austria) before medetomidine was administered (groups M and M+P+S) or before 118 
induction of anaesthesia with propofol (group P+S), 6 and 12 hours and 4 days 119 
thereafter. After coagulation and centrifugation (twice) at 3000g for 15 minutes using an 120 
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EBA-20 Hettich D-78532 centrifuge (Hettich GmbH & Co, Germany), serum 121 
samples were separated into aliquots and frozen at −70 °C until analysis. After thawing, 122 
the centrifugation procedure was repeated. Serum cTnI level was measured in singlicate 123 
using a commercial chemiluminescent microparticle immunoassay (CMIA) using an 124 
Architect i2000SR analyzer (Abbott Diagnostics, Germany). The analytical sensitivity 125 
of the ARCHITECT STAT Troponin-I assay was ≤ 0.01 ng mL-1. The validation of the 126 
ARCHITECT STAT Troponin-I assay in our laboratory revealed intra- and inter-assay 127 
coefficients of variation between 1.5% and 4.6% for three levels of commercial 128 
controls. Values lower than the detection limit of 0.006 ng mL-1 were recorded as 129 
0.0059 ng mL-1 for the purpose of statistical analysis. 130 
 131 
Statistical analysis 132 
Normal distribution of data was tested by the Shapiro-Wilk test. Differences between 133 
groups with detectable and undetectable concentration of serum cTnI regarding MAP 134 
and HR at basal values were compared using the Mann-Whitney Rank Sum test. Serum 135 
cTnI values at different sampling times were evaluated using the Friedman repeated 136 
measures analysis of variance on ranks. The Kruskal Wallis analysis of variance was 137 
used for comparison of serum cTnI concentrations, HR and MAP at all time points 138 
regarding different protocols. Differences with values of p < 0.05 were considered 139 
significant. SPSS for Windows ver. 22.0 (Armonk, NY: IBM Corp., USA) was used for 140 
all analyses. Data are presented as mean ± standard deviation. 141 
 142 
Results 143 
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A total of 66 dogs completed the study of which 20 were sedated for radiography and 144 
46 underwent general anaesthesia for gastroscopy. A total of 11 males and 9 females 145 
weighing 17.2 ± 13.2 kg and aged 69.9 ± 32.9 months were included in group M; 11 146 
males and 9 females weighing 10.7 ± 10.1 kg and aged 41.1 ± 25.2 months were 147 
included in group P+S; and 10 males and 16 females weighing 19.4 ± 11.8 kg and aged 148 
44.3 ± 25.1 months were included in group M+P+S. The dose of propofol administered 149 
to achieve endotracheal intubation in group P+S and M+P+S was 6.5 ± 0.8 and 1.9 ± 150 
0.6 mg kg-1, respectively.  151 
In group M, cTnI concentration was above the detection limit in nine out of 20 dogs 152 
(45%) before sedation. Serum cTnI concentration increased 6 and 12 hours and 4 days 153 
after sedation when compared to the basal values (p = 0.007, p = 0.002, and p = 0.016, 154 
respectively) (Fig. 1). In group P+S, cTnI concentration was above the detection limit in 155 
four out of 20 dogs (20%) before anaesthesia. An increase was observed at 6 and 12 156 
hours after anaesthesia when compared to the basal values (p = 0.035 and p < 0.001, 157 
respectively) (Fig. 2). In group M+P+S, cTnI concentration was above the detection 158 
limit in nine out of 26 dogs (34.6%) before anaesthesia. There was an increase in cTnI 159 
concentration at 6 and 12 hours after anesthesia when compared to basal values (p < 160 
0.001) (Fig. 3). 161 
Serum cTnI concentrations did not differ between groups at baseline as well as 6 hours 162 
and 4 days after sedation or anaesthesia. At 12 hours, cTnI concentrations were lower in 163 
group M+P+S when compared to group M (p = 0.006) and to group P+S (p = 0.022) 164 
(Fig. 4).  165 
There was no significant difference in HR between groups before sedation/anaesthesia. 166 
A lower HR (p < 0.001) was observed during sedation/anaesthesia in groups M and 167 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
M+P+S when compared to group P+S (Table 1). There was no significant difference in 168 
MAP between groups before sedation/anaesthesia. A higher MAP (p < 0.001) was 169 
observed during sedation/anaesthesia in groups M and M+P+S compared to group P+S 170 
(Table 2). 171 
 172 
Discussion 173 
 174 
This study documents an increase of cTnI after medetomidine sedation or anaesthesia 175 
with propofol and sevoflurane with or without premedication with medetomidine in 176 
dogs presented for non-surgical interventions. Singletary et al. (2010) investigated the 177 
effect of IV medetomidine (0.01 mg kg-1) combined with IV butorphanol (0.2 mg kg-1) 178 
on serum cTnI concentrations in dogs. The dose of medetomidine used was four-times 179 
lower than that in this study. In the study of Singletary et al. (2010), serum cTnI 180 
concentrations were below the detection limit at all sampling times (6, 18 and 24-hours 181 
post-sedation) in all but three out of 20 dogs; two of the three dogs had serum cTnI 182 
concentrations above the detection limit at all sampling times, including prior to 183 
sedation. Singletary et al. (2010) used the Immulite assay (Immulite 2000 Immunoassay 184 
system; Siemens Healthcare Global) with an analytical sensitivity (minimum detectable 185 
concentration) of 0.2 ng mL-1 (O'Brien et al. 2006) for the determination of serum cTnI 186 
concentration. Saunders et al. (2009) and Cilli et al. (2010) also used an Immulite assay. 187 
Saunders et al (2009) reported that zero of 20 dogs had a preanaesthetic cTnI 188 
concentration above the detection limit and Cilli et al. (2010) reported that only 12 out 189 
of 105 (11.4%) dogs had preanesthetic cTnI concentrations above the detection limit.  190 
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The assay used in this study (ARCHITECT STAT Troponin-I) has a much higher 191 
analytical sensitivity with a much lower detection limit of 0.006 ng mL-1, which enables 192 
more accurate determination of serum cTnI concentration. This is probably the reason 193 
that in this study a higher number of dogs, 22 out of 66 (33%), had serum cTnI 194 
concentrations above the detection limit already prior to sedation or anaesthesia in 195 
comparison to the studies of Saunders et al. (2009), Cilli et al. (2010) and Singletary et 196 
al. (2010).  Thus far, only Verbiest et al. (2013) used the same cTnI assay as was used 197 
in this study. Preanaesthetic cTnI concentrations in their study were above the level of 198 
detection in 11 out of 18 dogs (61%). These results suggest that selection of an assay 199 
with high analytical sensitivity and a low detection limit is of great importance for 200 
reliable interpretation of changes in cTnI concentrations. 201 
The cardiovascular effects of medetomidine are dose-related and include bradycardia, 202 
decreased cardiac output, vasoconstriction and arrhythmias (Ko et al. 2000). 203 
Significantly higher serum cTnI concentration in group M compared to group M+P+S at 204 
12 hours after sedation/anaesthesia cannot be attributed to medetomidine, since both 205 
groups of dogs were administered the same dose of medetomidine, which was 206 
antagonized with atipamezole 35 minutes later. Also, there were no differences between 207 
groups in terms of blood pressure and heart rate during sedation/anaesthesia. However, 208 
medetomidine sedated dogs breathed room air during sedation while those premedicated 209 
with medetomidine and anaesthetized with propofol and sevoflurane breathed oxygen 210 
during anaesthesia.  211 
Ko et al. (2007) investigated oxygenation status of dogs sedated with the same dose of 212 
medetomidine (0.04 mg kg-1 IV) as that used in this study and compared dogs breathing 213 
room air or oxygen supplemented via a face mask (3 L minute-1). One of seven dogs 214 
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breathing room air in their study had a hypoxemic episode 10 minutes after 215 
medetomidine administration [arterial partial pressure of oxygen (PaO2) of 59 mmHg], 216 
and the rest of the dogs had PaO2 values between 69 and 93 mmHg. Likewise, Raekallio 217 
et al. (2009) observed a slight decrease of PaO2 five minutes after medetomidine 218 
administration (0.02 mg kg-1 IV); PaO2 further decreased after addition of L-methadone 219 
(0.1 mg kg-1) to 55 mmHg. The authors of these studies therefore recommended 220 
oxygenation of dogs during sedation with medetomidine alone or in combination with 221 
opioids.  222 
A limitation of our study is that arterial blood gas analysis was not performed to detect 223 
hypoxaemia. Detection of hypoxaemia with pulse oximetry failed in medetomidine 224 
sedated dogs because they did not tolerate pulse oximetry probe on the tongue or the 225 
monitor reported errors during reading. However, according to the results of the study 226 
of Ko et al. (2007), it is reasonable to suspect that dogs which breathed room air during 227 
sedation with medetomidine in this study experienced a certain extent of hypoxia during 228 
sedation 229 
Dexmedetomidine IV at 0.001 to 0.004 mg kg-1 significantly increases coronary 230 
vascular resistance and mildly reduces coronary blood flow in enflurane-anaesthetized 231 
dogs (Flacke et al. 1993), which indicates that the local vasoconstriction action of 232 
medetomidine may restrict oxygen supply to the myocardium leading to potential 233 
myocardial hypoxia and release of cTnI. Unbound cytoplasmatic troponin is released 234 
within 4 to 6 hours of myocardial injury and reaches a peak concentration at 12 to 24 235 
hours, while release of structural cTnI due to ongoing myocardial injury leads to a 236 
second peak 2 to 4 days after injury (Wolfe Barry et al. 2008). In this study, increased 237 
serum cTnI concentrations were detected 6 and 12 hours after sedation/anaesthesia in all 238 
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groups of dogs, but remained increased up to 4 days in medetomidine sedated dogs 239 
only. This group of dogs breathed room air during sedation, while the other two groups 240 
breathed oxygen during anaesthesia. We presume that the hypoxic insult was severe 241 
enough only in medetomidine sedated dogs to also cause a release of structural cTnI, 242 
which peaks 2 to 4 days after the myocardial injury (Wolfe Barry et al. 2008). 243 
It is interesting that serum cTnI concentration was significantly lower 12 hours after 244 
anaesthesia in the M+P+S group in comparison to the P+S group, in which the dogs had 245 
significantly lower arterial blood pressure during anaesthesia. Medetomidine given IM 246 
or IV at or above 0.03 mg kg-1 transiently increases arterial blood pressure (Vainio & 247 
Palmu 1989; Cullen & Reynoldson 1993) through stimulation of peripheral postsynaptic 248 
α2-receptors in vascular walls (Savola et al. 1986; Savola 1989). Because of the 249 
anaesthetic sparing effect of medetomidine (Vainio 1991; Cullen & Reynoldson  1993; 250 
Lagerweij et al. 1993; Sap & Hellebrekers 1993; Hammond & England  1994; Thurmon 251 
et al. 1994), a much lower dose of propofol (1.92 ± 0.63 versus 6.5 ± 0.76 mg kg-1) was 252 
used for induction and a lower dose of sevoflurane (3% versus 4.5%) was used for 253 
maintenance of anaesthesia in the M+P+S group compared to the P+S group. Lower 254 
doses of propofol and sevoflurane in combination with medetomidine-induced 255 
vasoconstriction in the M+P+S group resulted in significantly higher arterial blood 256 
pressure and probably better tissue perfusion in this group. However, both anaesthetic 257 
protocols caused only mild myocardial injury as evidenced by increased serum cTnI 258 
concentration at 6 and 12 hours after anaesthesia but not 4 days later, which corresponds 259 
to the release of only unbound cytoplasmatic troponin.  260 
Another  limitation of this study might be that we did not use a cTnI assay of sufficient 261 
sensitivity to quantify and investigate changes in cTnI concentrations. However, the 262 
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lower limit of detection of the assay used in this study was very low (0.006 ng mL-1) 263 
and is the same as in the high-sensistivity cTnI assay used by Winter et al. (2014) and 264 
Winter et al. (2017). Moreover, the results of this study apply only to adult dogs aged up 265 
to 10 years and classified as ASA 1 or 2. Younger or older dogs were not recruited as 266 
this was clinical study and use of medetomidine at 0.04 mg kg-1 IV would not be 267 
appropriate due to pronounced medetomidine cardiovascular effects (Vainio & Palmu 268 
1989; Cullen & Reynoldson 1993). 269 
In conclusion, our results indicate that (1) anaesthesia with propofol and sevoflurane 270 
with or without premedication with medetomidine causes subclinical myocardial 271 
damage as evidenced by short-lived increased serum cTnI concentrations; (2) in dogs 272 
anaesthetized with propofol and sevoflurane, serum cTnI concentrations increase less 273 
when they are premedicated with medetomidine; (3) only in medetomidine-sedated 274 
dogs breathing room air was the hypoxic insult severe enough to cause increased serum 275 
cTnI concentration up to 4 days, which corresponds to the release of structural cTnI; (4) 276 
even if sedation with medetomidine appears to be a less invasive procedure than general 277 
anaesthesia in the eyes of the dog owner, and the dog may recover “normally” when it is 278 
breathing room air, supplementation with oxygen during sedation is necessary to 279 
prevent hypoxemia and ongoing myocardial injury. 280 
 281 
References 282 
 283 
Burgener IA, Kovacevic A, Mauldin GN et al. (2006) Cardiac troponins as indicators of 284 
acute myocardial damage in dogs. J Vet Intern Med 20, 277-283. 285 
 286 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Cilli F, Alibhai HIK, Armitage-Chan E et al. (2010) Incidence of elevation of cardiac 287 
troponin I prior to and following routine general anaesthesia in dogs. Vet Anaesth 288 
Analg 37, 409-416. 289 
 290 
Cullen LK, Reynoldson JA (1993) Xylazine or medetomidine premedication before 291 
propofol anaesthesia. Vet Rec 132, 378-383. 292 
 293 
Flacke WE, Flacke JW, Bloor BC et al. (1993) Effects of dexmedetomidine on systemic 294 
and coronary hemodynamics in the anesthetized dog. J Cardiothorac Vasc Anesth 7, 41-295 
49. 296 
 297 
Hammond RE, England GCW (1994) The effect of medetomidine premedication upon 298 
propofol induction and infusion anaesthesia in the dog. J Vet Anaesth 21, 24-28. 299 
 300 
Hector RC, Rezende ML, Mama KR et al. (2017) Effects of constant rate infusions of 301 
dexmedetomidine or MK-467 on the minimum alveolar concentration of sevoflurane in 302 
dogs. Vet Anaesth Analg 44, 755-765.   303 
 304 
 305 
Ko JC, Fox SM, Mandsager RE (2000) Sedative and cardiorespiratory effects of 306 
medetomidine, medetomidine-butorphanol, and medetomidine-ketamine in dogs. J Am 307 
Vet Med Assoc 216, 1578-1583.  308 
 309 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Ko JCH, Weil AB, Kitao T et al. (2007) Oxygenation in medetomidine-sedated dogs 310 
with and without 100% oxygen insufflation. Vet Ther 8, 51-60. 311 
 312 
Lagerweij E, Hall LW, Nolan AM (1993) Effects of medetomidine premedication on 313 
propofol infusion anesthesia in dogs. J Vet Anaesth 20, 78-83. 314 
 315 
Moran-Muñoz R, Ibancovichi JA, Gutierrez-Blanco E, et al. (2014) Effects of lidocaine, 316 
dexmedetomidine or their combination on the minimum alveolar concentration of 317 
sevoflurane in dogs. J Vet Med Sci 76, 847-53 318 
 319 
O’Brien PJ, Smith DE, Knechtel TJ et al. (2006) Cardiac troponin I is a sensitive, 320 
specific biomarker of cardiac injury in laboratory animals. Lab Anim 40, 153-171. 321 
 322 
Pelander L, Hagman R, Häggström J (2008) Concentrations of cardiac troponin I before 323 
and after ovariohysterectomy in 46 female dogs with pyometra. Acta Vet Scand 50, 35. 324 
 325 
Raekallio MR, Räihä MP, Alanen MH et al. (2009) Effects of medetomidine, L-326 
methadone, and their combination on arterial blood gases in dogs. Vet Anaesth Analg 327 
36, 158-161. 328 
 329 
Sap R, Hellebrekers LJ (1993) Medetomidine/propofol anaesthesia for gastroduodenal 330 
endoscopy in dogs. J Vet Anaesth 20, 100-102. 331 
 332 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Saunders A, Hanzlicek AS, Martinez EA et al. (2009) Assessment of cardiac troponin I 333 
and C-reactive protein concentrations associated with anesthetic protocols using 334 
sevoflurane or a combination of fentanyl, midazolam, and sevoflurane in dogs. Vet 335 
Anaesth Analg 36, 449-456. 336 
 337 
Savola JM, Ruskoaho H, Puurunen J et al. (1986) Evidence for medetomidine as a 338 
selective and potent agonist at alpha-2-adrenoceptors. J Auton Pharmacol 5, 275-284. 339 
 340 
Savola JM (1989) Cardiovascular actions of medetomidine and their reversal by 341 
atipamezole. Acta Vet Scand Suppl 85, 39-47. 342 
 343 
Singletary GE, Saunders AB, Saunders WB et al. (2010) Cardiac troponin I 344 
concentrations following medetomidine-butorphanol sedation in dogs. Vet Anaesth 345 
Analg 37, 342-346. 346 
 347 
Sleeper MM, Clifford CA, Laster LL (2001) Cardiac troponin I in the normal dog and 348 
cat. J Vet Intern Med 15, 501-3. 349 
 350 
Thurmon JC, Ko JCH, Benson GJ et al. (1994) Hemodynamic and analgesia effects of 351 
propofol infusion in medetomidine-premedicated dogs. Am J Vet Res 55, 563-567. 352 
 353 
Vainio O, Palmu L (1989) Cardiovascular and respiratory effects of medetomidine in 354 
dogs and influence of anticholinergics. Acta Vet Scand 30, 401-408. 355 
 356 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Vainio O (1991) Propofol infusion anaesthesia in dogs premedicated with 357 
medetomidine. J Vet Anaesth 18, 35-37. 358 
 359 
Verbiest T, Binst D, Waelbers T et al. (2013). Perioperative changes in cardiac troponin 360 
I concentrations in dogs. Res Vet Sci 94, 446-448. 361 
 362 
Winter RL, Saunders AB, Gordon SG et al. (2014) Analytical validation and clinical 363 
evaluation of a commercially available high-sensitivity immunoassay for the 364 
measurement of troponin I in humans for use in dogs. J Vet Cardiol 16, 81-9.  365 
 366 
Winter RL, Saunders AB, Gordon SG et al. (2017) Biologic variability of cardiac 367 
troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve 368 
disease using standard and high-sensitivity immunoassays. Vet Clin Pathol 46, 299-307.  369 
 370 
Wolfe Barry JA, Barth JH, Howell SJ (2008) Cardiac troponins: their use and relevance 371 
in anaesthesia and critical care medicine. Contin Educ Anaesth Crit Care Pain 8, 62-66. 372 
373 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
Figure Legends 374 
 375 
Figure 1 Serum cardiac troponin I (cTnI) concentrations before sedation with 376 
medetomidine (0.04 mg kg-1 IV; n = 20), 6 and 12 hours and 4 days thereafter. The dogs 377 
breathed room air. Each line represents data from a single dog. 378 
 379 
Figure 2 Serum cardiac troponin I (cTnI) concentrations before the dogs (n = 20) were 380 
induced to anaesthesia with propofol (6.5 ± 0.76 mg kg-1 IV) and anaesthetized with 381 
sevoflurane (4.5% vaporizer setting) in oxygen, 6 and 12 hours and 4 days thereafter. 382 
Each line represents data from a single dog. 383 
 384 
Figure 3 Serum cardiac troponin I (cTnI) concentrations before the dogs (n = 26) were 385 
premedicated with medetomidine (0.04 mg kg-1 IV), induced to anaesthesia with 386 
propofol (1.92 ± 0.63 mg kg-1) and anaesthetized with sevoflurane (3% vaporizer 387 
setting) in oxygen, 6 and 12 hours and 4 days thereafter. Each line represents data from 388 
a single dog. 389 
 390 
Figure 4 Serum cardiac troponin I (cTnI) concentrations 12 hours after sedation with 391 
medetomidine (M group) or anaesthesia  with propofol and sevoflurane (P+S group)  or 392 
with medetomidine, propofol and sevoflurane (M+P+S group); ° represent outliers 393 
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Table 2 Mean arterial blood pressure (mmHg) during sedation with medetomidine (group M), 
anaesthesia with propofol and sevoflurane (group P+S) and anaesthesia with propofol and 
sevoflurane after medetomidine premedication (group M+P+S) 
  M P+S M+P+S 
All dogs 
n 
 
20 20 26 
MAP (mmHg)  
 
106 (81–117)* 
 
91 (74–105) 
 
105 (87–124)* 
cTnI above 
detection limit 
before S/A 
n 
 
9 4 9 
MAP (mmHg) 
 
105 (48–115)* 
 
90 (75–105) 
 
108 (100–122)* 
cTnI below 
detection limit 
before S/A 
n 
 
11 16 17 
MAP (mmHg) 
 
108 (81–117)* 
 
92 (74–104) 
 
103 (87–124)* 
Data are presented as median (range). *Significantly higher mean arterial blood pressure 
compared to the P+S group 
cTnI, cardiac troponin I; n, number of dogs; MAP, mean arterial blood pressure; S/A, 
sedation/anaesthesia 
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Table 1 Heart rate during sedation with medetomidine (group M), anaesthesia with propofol 
and sevoflurane (group P+S) and anaesthesia with propofol and sevoflurane after 
medetomidine premedication (group M+P+S) 
  M P+S M+P+S 
All dogs 
n 20 20 26 
HR (beats minute-1) 87 (59–105) * 132 (99–152) 89 (61–98)* 
cTnI above 
detection limit 
before S/A 
n 9 4 9 
HR (beats minute-1) 89 (59–105)* 132 (99–152) 92 (77–96)* 
cTnI below 
detection limit 
before S/A 
n 11 16 17 
HR (beats minute-1) 86 (60–105)* 132 (107–145) 84 (61–98)* 
Data are presented as median (range). *Significantly lower heart rate compared to the P+S 
group 
cTnI, cardiac troponin I; n, number of dogs; HR, heart rate; S/A, sedation/anaesthesia 
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